Clinical Trials Logo

Aortic Regurgitation clinical trials

View clinical trials related to Aortic Regurgitation.

Filter by:

NCT ID: NCT06101888 Recruiting - Clinical trials for Aortic Regurgitation

Safety and Effectiveness of TaurusTrioâ„¢ Heart Valve System in Patients With Severe Aortic Regurgitation (AR)

Start date: August 1, 2023
Phase: N/A
Study type: Interventional

To evaluate the safety and effectiveness of the TaurusTrioâ„¢ Heart Valve System in a patient population with symptomatic severe AR requiring replacement/repair of their native aortic valve that are at high risk for open surgical aortic valve replacement/repair (SAVR).

NCT ID: NCT06034028 Recruiting - Clinical trials for Aortic Valve Disease

J-Valve TF Early Feasibility Study

JVTF EFS
Start date: October 16, 2023
Phase: N/A
Study type: Interventional

The main objective of this study is to assess the preliminary safety and effectiveness of the J-Valve TF System in patients with symptomatic severe native aortic regurgitation who are judged by a multi-disciplinary heart team to be eligible for the device and to be at high risk for open surgical aortic valve replacement.

NCT ID: NCT05774808 Completed - Clinical trials for Functional Mitral Regurgitation

Fate of Moderate Secondary Mitral Regurgitation in Patients Undergoing Aortic Valve Surgery for Severe Aortic Regurgitation

Start date: February 2, 2022
Phase:
Study type: Observational

Patients with severe aortic regurgitation (AR) may be affected, in many cases, by a concomitant moderate or severe mitral regurgitation (MR). Tethering of the mitral valve leaflets and/or annular dilatation, both consequences of left ventricular dilatation, represent the most common mechanisms underlying the development of MR which can therefore be defined as "secondary" in this case. When both mitral and aortic regurgitation are severe, patients show a decreased survival due to the pathophysiological consequences of the combination of these pathological conditions. In this case, surgery on both diseased valves is required to interrupt the natural history of the disease and is widely supported by current guidelines. On the other hand, little is known about the fate and prognostic implications of moderate MR secondary to severe AR and whether or not it should be treated at the time of aortic valve surgery. For this condition, the current guidelines do not provide specific recommendations, referring generically to the decision of the Heart Team. To date, there are few data describing the evolution of moderate MR in patients undergoing surgery for severe AR and insufficient data to support recommendations regarding the treatment of moderate MR concurrently with treatment of AR, so that this decision is now entrusted to the evaluation of the Heart Team. It is therefore desirable to evaluate the outcomes of these patients. The aim of this study is to evaluate the short- and long-term fate of secondary moderate MR in patients undergoing aortic valve replacement for severe AR.

NCT ID: NCT05774795 Completed - Clinical trials for Mitral Regurgitation

LOng-Term Fate of Moderate Aortic Regurgitation Left Untreated at the Time of Mitral Valve Surgery

Start date: March 24, 2021
Phase:
Study type: Observational

Multivalvular heart disease is a highly prevalent clinical condition that comprises 14.6% of the patients undergoing valvular surgery. Specifically, aortic valve regurgitation (AR) can be present in a considerable proportion of patients undergoing mitral valve (MV) surgery. In the Society of Thoracic Surgeons database, con- comitant aortic and mitral surgery accounted for 57.8% of the total multivalvular procedures with an unadjusted mortality rate of 10.7%. When both the aortic and MVs exhibit severe disease, con- comitant valve surgery is well-accepted by the surgical commu- nity and supported by current guidelines. On the other hand, when the aortic valve (AV) shows only moderate regurgita- tion, which would not be surgically treated if singly present, the appropriate management of the AV pathology at the time of MV surgery is still under debate. The American College of Cardiology guidelines state that aortic valve replacement (AVR) is reasonable (class IIa) in patients with moderate AR (stage B) while undergoing surgery on the ascend- ing aorta, a coronary artery bypass graft or MV surgery (level of evidence: C). Conversely, the latest European Society of Cardiology guidelines on valvular heart disease define as con- troversial the decision to treat the AV in patients with moderate AR who undergo MV surgery, considering the slow progression of this disease. In this group of patients, they advocate a heart team approach that will take into account the aetiology of AR, the life expectancy of the patient, the operative risk and other clinical factors. This disagreement may lead to uncertainty about how patients with less than severe AR should be managed during MV surgery, especially considering the burden of double-valve surgical procedures. The goal of this study is to evaluate the immediate and long- term outcomes, including the need for a new procedure on the AV, in patients with moderate AR at the time of MV surgery.

NCT ID: NCT05737264 Recruiting - Clinical trials for Transcatheter Aortic Valve Replacement

TAVR in Adults With Pure Severe Aortic Regurgitation

SENSE-AR
Start date: December 1, 2022
Phase:
Study type: Observational

The study aimed to evaluate the efficacy and safety of transcatheter aortic valve replacement (TAVR) in patients with severe native valve aortic insufficiency. It is a multicentre, observational cohort study. The primary endpoint consisted of a composite of all-cause death, disabling stroke, or rehospitalization for heart failure at 12 months postoperatively. According to previous research results and opinions of expert groups, the sample size was expected to be 76 cases.

NCT ID: NCT05714293 Enrolling by invitation - Clinical trials for Aortic Valve Stenosis

CT-evaluation of Coronary Ostia Height After Surgical Aortic Valve Replacement.

CORONATE
Start date: January 11, 2023
Phase: N/A
Study type: Interventional

The goal of this interventional, single-center study is to demonstrate if there is a change in the coronary ostia height after surgical aortic valve replacement and if it depends on the type of prosthesis or surgical technique used. The study involves patients undergoing elective surgical aortic valve replacement with a bioprosthesis. Participants enrolled will undergo a CT scan before and after surgery (at least 90 days after surgery) to analyze coronary ostia height.

NCT ID: NCT05515848 Completed - Clinical trials for Aortic Regurgitation

Aortic Valve-sparing Root Replacement, According to the Inclusion Technique Described by Tirone David

AORTLANTIC
Start date: November 7, 2021
Phase:
Study type: Observational

Retrospective observational study of all patients undergoing aortic root surgery with aortic valve conservation, using the inclusion technique described by Tirone David, between January 1, 2004 and December 31, 2020, at six centers (Nantes - Rennes - Brest - Angers - Tours [two centers]). The main objective of this study is to evaluate the survival without re-intervention for aortic valve dysfunction (surgery or TAVI).

NCT ID: NCT05409378 Withdrawn - Clinical trials for Aortic Regurgitation

HLT® Meridian® TAVR Valve System Early Feasibility Study for Aortic Regurgitation

RIVAL - AR EFS
Start date: July 8, 2022
Phase: N/A
Study type: Interventional

To evaluate the safety and performance of The Meridian® TAVR Valve in patients with severe aortic regurgitation who present at high risk for aortic valve replacement surgery.

NCT ID: NCT05332184 Completed - Clinical trials for Aortic Regurgitation

Cardiac T1 Mapping Enables Risk Prediction of LV Dysfunction After Surgery for Aortic Regurgitation

Start date: July 1, 2016
Phase:
Study type: Observational

To assess whether cardiac T1 mapping for detection of myocardial fibrosis enables preoperative identification of patients at risk for early left ventricular dysfunction after surgery of aortic regurgitation.

NCT ID: NCT05319171 Not yet recruiting - Clinical trials for Aortic Regurgitation

Performance of Currently Available traNscaTHEter Aortic Valve Platforms in Inoperable Patients With Pure Aortic regurgitatiON of a Native Valve. The PANTHEON International Project.

PANTHEON
Start date: May 2022
Phase:
Study type: Observational [Patient Registry]

- To investigate the performance of currently available THVs in terms of safety and efficacy - To evaluate potential predictors of THV embolization or migration (TVEM) - To assess the impact of TVEM on prognosis